Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism-Reference-Cited by-同舟云学术

Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism

Published:2024-05-08 Issue:6 Volume:21 Page:2740-2750
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Subash Sandhya¹,Singh Dilip K.¹,Ahire Deepak¹^ORCID,Khojasteh S. Cyrus²,Murray Bernard P.³,Zientek Michael A.⁴,Jones Robert S.²,Kulkarni Priyanka⁵,Zubair Faizan⁴,Smith Bill J.⁶,Heyward Scott⁷,Leeder J. Steven⁸,Prasad Bhagwat¹^ORCID

Affiliation:

1. College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington 99202, United States

2. Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California 94080, United States

3. Drug Metabolism, Gilead Sciences, Inc., Foster City, California 94404, United States

4. Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., San Diego, California 92121, United States

5. Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, United States

6. Terminal Phase Consulting LLC, Colorado Springs, Colorado 94404, United States

7. BioIVT, Inc., Baltimore, Maryland 21227, United States

8. Department of Pediatrics, Children’s Mercy Hospital, Kansas City, Missouri 64108, United States

Funder

Genentech

Takeda Pharmaceutical Company

Gilead Sciences

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c01147

Reference55 articles.

1. Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery

2. Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

3. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

4. Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans

5. Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and In Vitro Methods